IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Fresenius Kabi Buys Indian Generics and API Firm

6:56 AM MDT | April 28, 2008 | Deepti Ramesh

Fresenius Kabi (Bad Homburg, Germany), a unit of health care group Fresenius SE, says it has acquired 73.3% stake in Dabur Pharma (New Delhi) for about €139 million ($224 million). Fresenius Kabi says it has also offered to acquire a further 20% stake in Dabur Pharma for Rupees 76.50/share. The two companies have signed a share purchase agreement, and the transaction awaits regulatory approval, Fresenius Kabi says. Burman: India pharma market is attractive. Dabur Pharma is a leading global supplier of generic drugs and active pharmaceutical ingredients...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa